Concurrent chemoradiotherapy with pirarubicin and 5-fluorouracil for resectable oral and maxillary carcinoma.

Abstract

OBJECTIVE:

We present the response rate and adverse effects of our regimen of concurrent chemoradiotherapy with pirarubicin (THP) and 5-fluorouracil (5-FU) for oral and maxillary carcinoma.

PATIENTS AND METHODS:

Fifteen patients with oral (10 cases) or maxillary (5 cases) squamous cell carcinoma who underwent our concurrent chemoradiotherapy with the combination of intraarterial pirarubicin, intravenous continuous 5-fluorouracil, and radiation between March 2001 and February 2003 in our department were entered in this study. THP (5 mg/day) was infused into the lingual or maxillary artery one hour before radiation on days 1-5 and 8-12, while intravenous 5-FU (150 mg/m2/day) was instilled continuously on days 1-5, 8-12, 15-19, and 22-26 in accordance with the radiation schedule (2 Gy/day). Consequently, total doses of THP, 5-FU, and radiation were 50 mg, 3000 mg/m2 and 40 Gy, respectively. After the treatment series, response rate and adverse effects were evaluated.

RESULTS:

Response rate achieved 100% (12 cases exhibited a complete response and the remaining 3 a partial response). Notably, all 10 patients with oral carcinoma exhibited complete response. The main adverse effects were leucopenia (6/15) and mucositis (6/15), both of which were acceptable.

CONCLUSIONS:

This concurrent chemoradiotherapy is very useful for oral and maxillary carcinoma as a preoperative modality with remarkably high response rate and acceptable adverse events.

• Authors: Hiroyoshi Iguchi, Makoto Kusuki, Aki Nakamura, Hiroshi Nishiura, Akimori Kanazawa, Masahiro Takayama, Kishiko Sunami, Hideo Yamane
• Journal: Acta oto-laryngologica. Supplementum (Acta Otolaryngol Suppl) Issue 554 Pg. 55-61 (Oct 2004) ISSN: 0365-5237 [Print] Norway
• PMID: 15513513 (Publication Type: Journal Article)

Chemical References

• Antimetabolites, Antineoplastic
• Immunosuppressive Agents
• Doxorubicin
• pirarubicin
• Fluorouracil

Topics

• Aged
• Antimetabolites, Antineoplastic (adverse effects, therapeutic use)
• Carcinoma, Squamous Cell (therapy)
• Chemotherapy, Adjuvant
• Combined Modality Therapy
• Doxorubicin (adverse effects, analogs & derivatives, therapeutic use)
• Female
• Fluorouracil (adverse effects, therapeutic use)
• Humans
• Immunosuppressive Agents (adverse effects, therapeutic use)
• Inflammation (chemically induced)
• Leukopenia (chemically induced)
• Male
• Maxillary Neoplasms (therapy)
• Middle Aged
• Mouth Mucosa (drug effects, pathology)
• Mouth Neoplasms (therapy)
• Radiotherapy, Adjuvant
• Tomography, X-Ray Computed
• Treatment Outcome